search
Back to results

Omega-3 Fatty Acids and Insulin Sensitivity

Primary Purpose

Insulin Resistance

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Omega-3
placebo
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insulin Resistance

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  1. Age 18-65 years
  2. Insulin resistant (Homeostasis Model Assessment (HOMA) Insulin Resistance (IR) ≥2.6)

Exclusion criteria:

  1. Current use of omega-3 nutritional supplements
  2. Fasting plasma glucose ≥126 mg/dL
  3. Active coronary artery disease
  4. Participation in structured exercise (>2 times per week for 30 minutes or longer)
  5. Smoking
  6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)
  7. Renal failure (serum creatinine > 1.5mg/dl)
  8. Chronic active liver disease (AST>144 IU/L and alanine transaminase (ALT)>165 IU/L)
  9. Anti-coagulant therapy (warfarin/heparin)
  10. International normalized ratio (INR) >3
  11. Use of systemic glucocorticoids
  12. Chronic use of NSAIDS or aspirin
  13. Pregnancy or breastfeeding
  14. Alcohol consumption greater than 2 glasses/day
  15. Hypothyroidism
  16. Fish or shellfish allergy

Sites / Locations

  • Mayo Clinic in Rochester

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Omega-3

Placebo

Arm Description

Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.

Patients in this group will be supplemented with placebo capsules containing ethyl oleate.

Outcomes

Primary Outcome Measures

Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up
A 2-stage insulin clamp will be performed with titration of dextrose to maintain euglycemia. D2 glucose will be infused to evaluate hepatic glucose production at baseline and in response to insulin. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate (GIR) equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.

Secondary Outcome Measures

Beta Cell Function From Insulin Secretion Following Ingestion of a Mixed Meal at Baseline and 6 Month Follow up
Following consumption of a mixed meal, beta cell function will be evaluated from serial measurements of C-peptide. C-peptide was measured using a two-side immunometric assay using electrochemiluminescence detection.
Mitochondrial Function Determined by Muscle Biopsy at Baseline and 6 Month Follow up
Measurements of oxygen consumption in isolated mitochondria will be performed using a polarographic oxygen electrode.
Insulin Concentration Needed to Suppress Palmitate Appearance Rates (IC50(Palmitate)f)
Sensitivity of adipose tissue lipolysis to insulin suppression, was calculated as the insulin concentration needed to suppress palmitate appearance rates (ie, flux) by 50% (IC50(palmitate)f).
Senescent Cells
Tissue burden of senescent cells, which was measured by staining for senescence-associated B-galactosidase activity and expressed as the number per 100 nucleated positive cells.
Immunohistochemistry Assessments of Macrophage Burden
One week after the pancreatic clamp study, participants were provided a standardized meal before an overnight fast. The next morning an abdominal adipose tissue biopsy was collected, and the samples were analyzed for adipocyte size. Immunohistochemistry was used to assess macrophage burden (total (CD68), M1 (CD14) and M2 (CD206) macrophages per 100 adipocytes).
Macrophage Crown-like Structures
Macrophages surrounding dying or dead adipocytes form crown-like structures (CLSs). One week after the pancreatic clamp study, participants were provided a standardized meal before an overnight fast. The next morning an abdominal adipose tissue biopsy was collected, and the samples were analyzed for adipocyte size. Immunohistochemistry was used to assess the number of crown-like structures per 10 images.

Full Information

First Posted
September 11, 2012
Last Updated
January 18, 2017
Sponsor
Mayo Clinic
Collaborators
National Center for Advancing Translational Sciences (NCATS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Building Interdisciplinary Research Careers in Women's Health
search

1. Study Identification

Unique Protocol Identification Number
NCT01686568
Brief Title
Omega-3 Fatty Acids and Insulin Sensitivity
Official Title
Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
December 21, 2012 (Actual)
Primary Completion Date
October 30, 2014 (Actual)
Study Completion Date
June 8, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
National Center for Advancing Translational Sciences (NCATS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Building Interdisciplinary Research Careers in Women's Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.
Detailed Description
Dietary omega-3 polyunsaturated fatty acids (n-3 PUFA), which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from fish oil, prevent insulin resistance in rodents, but data in humans is ambiguous. No existing studies have systematically evaluated the influence of n-3 PUFAs on insulin sensitivity and beta cell function in insulin resistant, non-diabetic humans. The Investigators hypothesize that 6 months of oral supplementation of purified EPA/DHA (3.9g/day) will significantly improve hepatic and peripheral insulin sensitivity and beta cell responsiveness in insulin-resistant, non-diabetic individuals. Based on recent work in mice, the investigators also hypothesize that EPA/DHA will increase the content and function of mitochondria in skeletal muscle, measured using a combination of in vivo and in vitro methods. Overall, the investigators hypothesize that EPA+DHA supplementation will improve hepatic and peripheral insulin sensitivity in insulin resistant humans, and this improvement will be associated with mitochondrial biogenesis and attenuated lipid accumulation in skeletal muscle and liver. A sub-study was added in which participants receiving dietary omega-3 fatty acids or placebo supplements underwent abdominal subcutaneous adipose tissue biopsies to measure the content of total, pro- (M1) and anti- (M2) inflammatory macrophages (immunohistochemistry), crown-like structures (immunohistochemistry), and senescent cells (β-galactosidase staining), as well as a two-step euglycemic, pancreatic clamp with a stable-isotope labeled precursor ((U-13C)palmitate) infusion to determine the insulin concentration needed to suppress palmitate flux by 50% (IC50(palmitate)f).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Omega-3
Arm Type
Experimental
Arm Description
Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
Intervention Type
Drug
Intervention Name(s)
Omega-3
Other Intervention Name(s)
Essential fatty acids, Omega-3 fatty acids, Omega-3 polyunsaturated fatty acids, PUFAs, Lovaza
Intervention Description
Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
Intervention Type
Drug
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up
Description
A 2-stage insulin clamp will be performed with titration of dextrose to maintain euglycemia. D2 glucose will be infused to evaluate hepatic glucose production at baseline and in response to insulin. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate (GIR) equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.
Time Frame
Baseline, after 6 months of treatment
Secondary Outcome Measure Information:
Title
Beta Cell Function From Insulin Secretion Following Ingestion of a Mixed Meal at Baseline and 6 Month Follow up
Description
Following consumption of a mixed meal, beta cell function will be evaluated from serial measurements of C-peptide. C-peptide was measured using a two-side immunometric assay using electrochemiluminescence detection.
Time Frame
baseline, after 6 months of treatment
Title
Mitochondrial Function Determined by Muscle Biopsy at Baseline and 6 Month Follow up
Description
Measurements of oxygen consumption in isolated mitochondria will be performed using a polarographic oxygen electrode.
Time Frame
Baseline, after 6 months of treatment
Title
Insulin Concentration Needed to Suppress Palmitate Appearance Rates (IC50(Palmitate)f)
Description
Sensitivity of adipose tissue lipolysis to insulin suppression, was calculated as the insulin concentration needed to suppress palmitate appearance rates (ie, flux) by 50% (IC50(palmitate)f).
Time Frame
approximately after 6 months of treatment
Title
Senescent Cells
Description
Tissue burden of senescent cells, which was measured by staining for senescence-associated B-galactosidase activity and expressed as the number per 100 nucleated positive cells.
Time Frame
approximately after 6 months of treatment
Title
Immunohistochemistry Assessments of Macrophage Burden
Description
One week after the pancreatic clamp study, participants were provided a standardized meal before an overnight fast. The next morning an abdominal adipose tissue biopsy was collected, and the samples were analyzed for adipocyte size. Immunohistochemistry was used to assess macrophage burden (total (CD68), M1 (CD14) and M2 (CD206) macrophages per 100 adipocytes).
Time Frame
approximately after 6 months of treatment
Title
Macrophage Crown-like Structures
Description
Macrophages surrounding dying or dead adipocytes form crown-like structures (CLSs). One week after the pancreatic clamp study, participants were provided a standardized meal before an overnight fast. The next morning an abdominal adipose tissue biopsy was collected, and the samples were analyzed for adipocyte size. Immunohistochemistry was used to assess the number of crown-like structures per 10 images.
Time Frame
approximately after 6 months of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Age 18-65 years Insulin resistant (Homeostasis Model Assessment (HOMA) Insulin Resistance (IR) ≥2.6) Exclusion criteria: Current use of omega-3 nutritional supplements Fasting plasma glucose ≥126 mg/dL Active coronary artery disease Participation in structured exercise (>2 times per week for 30 minutes or longer) Smoking Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants) Renal failure (serum creatinine > 1.5mg/dl) Chronic active liver disease (AST>144 IU/L and alanine transaminase (ALT)>165 IU/L) Anti-coagulant therapy (warfarin/heparin) International normalized ratio (INR) >3 Use of systemic glucocorticoids Chronic use of NSAIDS or aspirin Pregnancy or breastfeeding Alcohol consumption greater than 2 glasses/day Hypothyroidism Fish or shellfish allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian Lanza, PhD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25852206
Citation
Lalia AZ, Johnson ML, Jensen MD, Hames KC, Port JD, Lanza IR. Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. Diabetes Care. 2015 Jul;38(7):1228-37. doi: 10.2337/dc14-3101. Epub 2015 Apr 7.
Results Reference
result
PubMed Identifier
28424185
Citation
Hames KC, Morgan-Bathke M, Harteneck DA, Zhou L, Port JD, Lanza IR, Jensen MD. Very-long-chain omega-3 fatty acid supplements and adipose tissue functions: a randomized controlled trial. Am J Clin Nutr. 2017 Jun;105(6):1552-1558. doi: 10.3945/ajcn.116.148114. Epub 2017 Apr 19.
Results Reference
derived

Learn more about this trial

Omega-3 Fatty Acids and Insulin Sensitivity

We'll reach out to this number within 24 hrs